Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide tablets, a generic prostate cancer treatment drug, for ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration ...

Zydus Lifesciences, Maruti Suzuki India, Dabur India, South Indian Bank, Allcargo Logistics, International Conveyors, NMDC, ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) ...

Royal Enfield's wholesales rose 11% to 86,978 units in September, driven by strong domestic demand and new model launches.

Zydus Lifesciences on Saturday said it has received approval from the US health regulator to produce generic prostate cancer ...